Business Context and Reporting Period
This Form 8-K is a current report filed by Virios Therapeutics, Inc. (not Dogwood Therapeutics, Inc., as indicated in the metadata) on May 24, 2023. The filing addresses a specific corporate event regarding the company's listing status on the Nasdaq Capital Market under the trading symbol VIRI.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding stock price rather than financial performance.
Material Changes
The primary material change reported is the company's regained compliance with the Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement. On May 24, 2023, Virios Therapeutics received confirmation from The Nasdaq Stock Market LLC that its common stock had maintained a closing bid price of at least $1.00 per share for ten consecutive business days.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The document does not disclose new risks or contingencies beyond the resolution of the prior non-compliance issue regarding the minimum bid price.
Investor Verification Checklist
- Verify the company name is Virios Therapeutics, Inc. (metadata reference to Dogwood Therapeutics is incorrect).
- Confirm the stock ticker symbol is VIRI on the Nasdaq Capital Market.
- Review the attached Exhibit 99.1 (Letter from Nasdaq) for the official confirmation of compliance.
- Note that this filing does not contain financial statements or operational updates.